The financials
Iovance Biotherapeutics, Inc. by the numbers
Iovance Biotherapeutics, Inc. (IOVA) reported revenue of $71M in Q1 2026 (quarter ended Mar 31, 2026), up 45% from the same quarter a year earlier. That came with a gross margin of 41% and net loss of $79M. For the full year FY2025, revenue was $264M (+61% year on year) and net income −$391M. Its largest product in Jun 2026 was Amtagvi at $91M, 91% of the disclosed total, well ahead of Proleukin at 8.7%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $71M | $49M | +45% |
| Gross profit | $29M | $6.6M | +338% |
| Operating income | −$81M | −$121M | n/a |
| Net income | −$79M | −$116M | n/a |
| Diluted EPS | −$0.19 | −$0.36 | n/a |
| Product | Revenue | Share |
|---|---|---|
| Amtagvi | $91M | 91% |
| Proleukin | $8.6M | 8.7% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $99.3M (+39%)
Amtagvi grew +68% year on yearProleukin +46% year on year
Segment Latestquarter on quarteryear on year
- Amtagvi$90.7M$90.7MQoQ +51%year on year +68%+51%+68%
- Proleukin$8.6M$8.6MQoQ -23%year on year +46%-23%+46%